

Market Outlook

Nifty slipped to 25,884, breaking below its short-term rising trendline, signalling fatigue after multiple failed attempts near 26,250. Momentum has turned weak, and downside pressure may extend if 25,800 breaks decisively. For tomorrow, resistance zones lie at 25,950 and 26,050, while support sits at 25,800 and 25,750. A close below 25,700 could trigger deeper selling toward 25,500; above 25,950, expect short-covering.

Key Indices Update

INDEX	CLOSE	CHANGE (%)
NIFTY	25884	-0.28
SENSEX	84587	-0.36
BANKNIFTY	58820	-0.02
INDIA VIX	12.24	-7.50

FII STATISTICS


FII F&O Data

Sector	Buy/Sell	Change in OI
Index Futures	-2315.54	-40.46%
Index Options	1046.94	-48.47%
Stock Futures	132.35	-3.50%
Stock Options	-446.87	-74.96%

FII & DII Cash Segment (Rs. In Crore)

Category	Amount	MTD	YTD
FII	785.00	-17227	-127447
DII	3912.00	62745	505195

FII Activity in Index Future



Amt in Crores


NIFTY 50 HIGH DELIVERY STOCKS

SYMBOL	DELIVERABLE QTY	CHG IN DLY RATIO VS PREV DAY	% CHG IN TRD QTY OVER PREV DAY
HDFCBANK	14345733	-14.5	-22.4
ETERNAL	12605738	1.45	-54.6
POWERGRID	8963727	-12.62	-75.67
TMPV	8240712	7.06	-0.74
RELIANCE	7863116	-17.24	-18.45
BEL	7595468	-7.03	-40.47
ICICIBANK	6815799	-10.33	-23.03
ONGC	6511959	-3.02	-43.41
NTPC	5561480	-9.78	-41.15
ITC	5192578	-15.67	-25.71


NIFTY

Nifty	26055.40
OI (In contracts)	182526
CHANGE IN OI (%)	24.22
PRICE CHANGE (%)	-0.44
IMPLICATION	SHORT BUILDUP

NIFTY (CLOSE VS OI)



NIFTY OPTION CHAIN




Long Buildup

Symbol	Price	Price %	OI	OI %
HUDCO	232.28	1.07	31404675	45.56
NCC	174.07	0.18	22774500	41.57
SAIL	132.8	0.45	137667700	40.03
ADANIGREEN	1017.3	0.30	22219200	28.53
LICHSGFIN	551.1	0.38	32645000	27.27


BANKNIFTY

Banknifty	59139.60
OI (In contracts)	37887
CHANGE IN OI (%)	33.37
PRICE CHANGE (%)	-0.18
IMPLICATION	SHORT BUILDUP

BANKNIFTY (CLOSE VS OI)



BANKNIFTY OPTION CHAIN



Short Buildup

Symbol	Price	Price %	OI	OI %
ADANIEN	2347.6	-2.87	14085456	46.89
RECLTD	353.45	-1.35	91006950	42.26
SUZLON	54.55	-0.75	233416000	39.34
LAURUSLABS	982.6	-0.15	15654450	38.64
HFCL	71.05	-0.77	115854900	37.48

Top 10 High PCR Ratio Stocks

SCRIP	PUT	CALL	P/C RATIO
VOLTAS	3871875	3432375	1.13
AUBANK	6335000	5719000	1.11
PETRONET	17292600	15860400	1.09
FEDERALBNK	44300000	41260000	1.07
HEROMOTOCO	2553750	2398350	1.06
CANBK	116316000	113271750	1.03
SBIN	39360750	40667250	0.97
GODREJCP	1919000	2050500	0.94
PERSISTENT	725400	792100	0.92
ABB	1005500	1101375	0.91

Top 10 Low PCR Ratio Stocks

SCRIP	PUT	CALL	P/C RATIO
KAYNES	862200	2296200	0.38
PATANJALI	3013200	7937100	0.38
TATASTEEL	109488500	290719000	0.38
TMPV	32537600	85120000	0.38
PPLPHARMA	6333125	16173125	0.39
SUZLON	80471150	205074800	0.39
IGL	4804250	11825000	0.41
NCC	8785800	21500100	0.41
DELHIVERY	9951700	23576150	0.42
TATACONSUM	2740100	6502650	0.42

NIFTY 50 SUPPORT-RESISTANCE LEVELS

SYMBOL	R1	R2	PP	S1	S2
ADANIENT	2441	2465	2426	2402	2387
ADANIPORTS	1500	1507	1491	1484	1474
APOLLOHOSP	7451	7505	7414	7361	7324
ASIANPAINT	2912	2927	2895	2880	2863
AXISBANK	1292	1306	1284	1270	1262
BAJAJ-AUTO	9137	9231	9003	8909	8775
BAJAJFINSV	2069	2093	2055	2031	2017
BAJFINANCE	1012	1023	1006	995	988
BEL	415	423	410	402	397
BHARTIARTL	2176	2190	2164	2151	2139
CIPLA	1531	1547	1521	1506	1496
COALINDIA	379	383	377	373	370
DRREDDY	1260	1285	1244	1219	1203
EICHERMOT	7333	7381	7260	7213	7140
ETERNAL	307	311	302	298	293
GRASIM	2746	2784	2725	2687	2666
HCLTECH	1644	1667	1630	1607	1593
HDFCBANK	1016	1025	1009	1000	993
HDFCLIFE	772	779	767	760	755
HINDALCO	790	800	784	774	768
HINDUNILVR	2451	2466	2439	2424	2413
ICICIBANK	1383	1391	1378	1370	1364
INDIGO	5933	6027	5877	5783	5727
INFY	1578	1598	1566	1546	1533
ITC	410	414	408	404	402

SYMBOL	R1	R2	PP	S1	S2
JIOFIN	305	308	303	300	299
JSWSTEEL	1140	1164	1126	1102	1089
KOTAKBANK	2116	2129	2104	2091	2079
LT	4062	4082	4046	4027	4011
M&M	3763	3811	3731	3683	3651
MARUTI	16165	16252	16107	16020	15962
MAXHEALTH	1184	1205	1171	1149	1137
NESTLEIND	1292	1306	1280	1266	1254
NTPC	329	332	327	324	321
ONGC	248	250	247	246	245
POWERGRID	280	283	277	274	271
RELIANCE	1558	1568	1551	1542	1535
SBILIFE	2035	2043	2026	2018	2010
SBIN	982	987	978	974	970
SHRIRAMFIN	844	853	836	826	818
SUNPHARMA	1795	1802	1787	1781	1772
TATACONSUM	1200	1210	1190	1180	1170
TATASTEEL	169	171	168	165	164
TCS	3193	3222	3171	3142	3121
TECHM	1528	1550	1500	1478	1450
TITAN	3943	3983	3920	3880	3857
TMPV	364	368	361	357	354
TRENT	4382	4430	4354	4306	4279
ULTRACEMCO	11766	11876	11699	11589	11522
WIPRO	250	252	248	246	245

Research Team

Name	Email ID
<i>Ajit Mishra</i>	ajit.mishra@religare.com
<i>Abhijeet Banerjee</i>	abhijeet.banerjee@religare.com
<i>Gaurav Sharma</i>	gauravsharma2@religare.com
<i>Ashwani Harit</i>	ashwani.harit@religare.com
<i>Divya Parmar</i>	divya.parmar@religare.com
<i>Rajan Gupta</i>	rajan.gupta1@religare.com
<i>Vivek Chandra</i>	vivek.chandra@religare.com
<i>Himanshu Gupta</i>	himanshu.gupta1@religare.com
<i>Vishvajeet Singh</i>	vishvajeet.singh1@religare.com

Disclaimer

Before you use this research report, please ensure to go through the disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 and Research Disclaimer at the following link: <https://www.religareonline.com/disclaimer>

Specific analyst(s) specific disclosure(s) inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 is/are as under:

Statements on ownership and material conflicts of interest, compensation– Research Analyst (RA) [Please note that only in case of multiple RAs, if in the event answers differ inter-se between the RAs, then RA specific answer with respect to questions under F(a) to F(j) below, are given separately]:

S. No.	Statement	Answer	
		Yes	No
	I/we or any of my/our relative has any financial interest in the subject company? [If answer is yes, nature of Interest is given below this table]		No
	I/we or any of my/our relatives, have actual/beneficial ownership of one percent. or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance?		No
	I/we or any of my/our relative, has any other material conflict of interest at the time of publication of the research report or at the time of public appearance?		No
	I/we have received any compensation from the subject company in the past twelve months?		No
	I/we have managed or co-managed public offering of securities for the subject company in the past twelve months?		No
	I/we have received any compensation for brokerage services from the subject company in the past twelve months?		No
	I/we have received any compensation for products or services other than brokerage services from the subject company in the past twelve months?		No
	I/we have received any compensation or other benefits from the subject company or third party in connection with the research report?		No
	I/we have served as an officer, director or employee of the subject company?		No
	I/we have been engaged in market making activity for the subject company?		No

Nature of Interest if answer to F(a) above is Yes:

..... Name(s) with Signature(s) of RA(s).

[Please note that only in case of multiple RAs and if the answers differ inter-se between the RAs, then RA specific answer with respect to questions under F(a) to F(j) above, are given below]

SS. No.	Name(s) of RA.	Signatures of RA	Serial Question of question which the signing RA needs to make a separate declaration / answer	Yes	No

Copyright in this document vests exclusively with RBL. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose, without prior written permission from RBL. We do not guarantee the integrity of any emails or attached files and are not responsible for any changes made to them by any other person.

No representations are being made about the performance or activities unless accompanied by data regarding performance, disclosures of all the risk factors, etc. and disclaimer that "Such representations are not indicative of future results